La-Iii en es it fr

La-Iii Brand names, La-Iii Analogs

La-Iii Brand Names Mixture

  • No information avaliable

La-Iii Chemical_Formula


La-Iii RX_link

La-Iii fda sheet

La-Iii msds (material safety sheet)


La-Iii Synthesis Reference

Reeder, Sternbach; U.S. Pat. 3,371,085 (1968)

La-Iii Molecular Weight

284.74 g/mol

La-Iii Melting Point


La-Iii H2O Solubility

Slightly soluble (50 mg/L)

La-Iii State


La-Iii LogP


La-Iii Dosage Forms

Tablets; Injectable solution

La-Iii Indication

Used in the treatment of severe anxiety disorders, as a hypnotic in the short-term management of insomnia, as a sedative and premedicant, as an anticonvulsant, and in the management of alcohol withdrawal syndrome.

La-Iii Pharmacology

Diazepam, a benzodiazepine, generates the same active metabolite as chlordiazepoxide and clorazepate. In animals, diazepam appears to act on parts of the limbic system, the thalamus and hypothalamus, and induces calming effects. Diazepam, unlike chlorpromazine and reserpine, has no demonstrable peripheral autonomic blocking action, nor does it produce extrapyramidal side effects; however, animals treated with diazepam do have a transient ataxia at higher doses. Diazepam was found to have transient cardiovascular depressor effects in dogs. Long-term experiments in rats revealed no disturbances of endocrine function. Injections into animals have produced localized irritation of tissue surrounding injection sites and some thickening of veins after intravenous use.

La-Iii Absorption

Essentially complete, with a bioavailability of 93%.

La-Iii side effects and Toxicity

Symptoms of overdose include somnolence, confusion, coma, and diminished reflexes. Respiration, pulse and blood pressure should be monitored.

La-Iii Patient Information

La-Iii Organisms Affected

Humans and other mammals